Ebola Passes 4,000 in DRC; FDA Eyes Melanoma and Rare-Disease Firsts
DRC Bundibugyo outbreak becomes second-worst Ebola epidemic on record; jalapeño recall hits 27 US states; FDA nears melanoma and rare-disease verdicts.
By Dr. Asher Knippel
This week in health: a Bundibugyo Ebola epidemic in Central Africa passes a sobering milestone, a salmonella recall ties restaurant meals to dozens of hospitalisations, and a pair of FDA action dates draw into focus for diseases that have long lacked answers.
Saturday, 8 August: DRC Ebola Outbreak Becomes Second-Largest in History
As of Saturday 8 August, the Democratic Republic of the Congo is reporting 4,209 confirmed cases and 1,916 deaths from an outbreak of Ebola disease caused by the Bundibugyo virus — making this the second-largest Ebola epidemic on record, surpassed only by the West Africa outbreak of 2013–2016. Five provinces are affected, with Ituri province bearing the heaviest burden: 3,636 confirmed cases and 1,551 deaths across 28 of its 36 health zones.
Bundibugyo virus, first identified in Uganda in 2007, is a distinct Ebolavirus species with a case fatality rate somewhat lower than Zaire ebolavirus but still severe. Current data show 828 recoveries and 595 patients in isolation. Doctors Without Borders (MSF) and the U.S. State Department reported active response operations as of 5 August; the CDC is coordinating international support. The ECDC has issued a risk communication noting that while the risk to the EU remains low, travellers to affected provinces should take precautions.
89 new confirmed cases were logged in the 24 hours to 8 August, the majority in Ituri (73 cases), with 12 in North Kivu and four in Haut Uele. Community transmission in remote areas and cross-border movement into Uganda remain the primary containment challenges.
Saturday, 8 August: Salmonella Javiana Linked to Jalapeño Peppers; 345 Ill Across 27 States
The CDC is investigating a multistate outbreak of Salmonella Javiana linked to jalapeño peppers. As of 10 August, 345 people across 27 US states have fallen ill and 36 have been hospitalised; no deaths have been reported. Taylor Fresh Foods recalled the peppers on 8 August, with products distributed to major retailers — including Walmart, Kroger, Target, and Whole Foods — bearing "Best If Used By" dates up to 16 August 2026.
Traceback data point to jalapeños grown in Sinaloa, Mexico, and distributed by Coast Citrus Distributors. Among 191 people interviewed, 177 (93%) reported eating at a Mexican-style restaurant in the days before falling ill, including Chipotle Mexican Grill and QDOBA locations. The FDA and CDC advise consumers to check their refrigerators and discard any recalled product; people who develop fever, diarrhoea, or abdominal cramps within 12–72 hours of eating jalapeños should contact a healthcare provider. Salmonella infections resolve on their own for most healthy adults, but young children, older adults, and those with weakened immune systems face a higher risk of severe illness.
Thursday, 6 August: FDA Approves Viral Immunotherapy Tudriqev for Treatment-Resistant Advanced Melanoma
On 6 August 2026, the FDA granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune), a genetically modified oncolytic virus derived from herpes simplex virus, in combination with nivolumab. The indication is for adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a PD-1 inhibitor–based regimen.
Melanoma that has stopped responding to immunotherapy is a difficult clinical problem with limited options. The approval follows two prior FDA rejections and is grounded in clinical trial data showing an objective response rate of approximately 25%, with responses lasting a median of nearly 14 months. The therapy works by injecting the engineered virus directly into accessible tumours; the virus replicates within cancer cells, triggering both direct tumour destruction and a broader immune response. The FDA assigned Breakthrough Therapy and Priority Review designations to the application. As a condition of accelerated approval, Replimune is required to conduct confirmatory post-approval trials to verify the clinical benefit observed in the response-rate endpoint.
July–August 2026: Maternal GBS6 Vaccine Shows Strong Phase 1/2 Results in Nature Medicine
Group B Streptococcus (GBS) is the leading infectious cause of newborn meningitis and sepsis globally, responsible for roughly 150,000 infant deaths a year. A maternal vaccine could confer protection by transferring antibodies across the placenta during the third trimester — but no licensed product yet exists.
A phase 1/2 trial of Pfizer's investigational hexavalent GBS conjugate vaccine (GBS6), published in Nature Medicine and co-led by researchers from Wits VIDA in South Africa, found the vaccine to be well-tolerated and immunogenic in both non-pregnant and pregnant women. The vaccine stimulated robust immune responses against all six clinically relevant GBS serotypes and resulted in efficient transfer of GBS-specific antibodies from vaccinated mothers to their babies at birth. Because this is a phase 1/2 trial, the primary objectives were safety and immunogenicity, not clinical efficacy; the study was not powered to measure whether fewer infants developed GBS disease. The findings support progression to the global phase 3 BEATRIX trial (NCT07160244), already recruiting at sites across North America, Europe, Africa, and Asia, with primary completion expected in November 2028.
August 2026: FDA Decision Expected for Garetosmab — Potentially the First Drug to Halt Abnormal Bone Formation in FOP
Fibrodysplasia ossificans progressiva (FOP) is one of medicine's rarest and most relentless conditions: the body progressively replaces muscles, tendons, and connective tissue with abnormal bone, gradually encasing the person in a second skeleton. Around 800 people are estimated to be living with FOP in the United States, and fewer than 5,000 worldwide. Until now, there has been no approved treatment.
An FDA decision is expected this month for garetosmab (Regeneron), a monoclonal antibody that blocks Activin A — a protein Regeneron researchers identified as critical to the abnormal bone-formation process in FOP. The Phase 3 OPTIMA trial found that both doses evaluated (3 mg/kg and 10 mg/kg) reduced the total number and volume of new heterotopic ossification lesions by more than 99% at 56 weeks, compared to placebo. The FDA accepted the Biologics License Application under Priority Review in February 2026. If approved, garetosmab would be the first — and only — disease-modifying treatment available for FOP, representing a potential turning point for a small community that has waited decades for a therapy.
August 2026: FDA Sets 27 August PDUFA Date for Gilead's Once-Daily HIV Combination Bictegravir + Lenacapavir
The FDA has set 27 August 2026 as the PDUFA action date for Gilead's New Drug Application for a single-tablet, once-daily regimen combining bictegravir (75 mg) and lenacapavir (50 mg), intended for adults living with HIV who are already virologically suppressed. The combination pairs two complementary mechanisms: bictegravir is an integrase strand transfer inhibitor (INSTI) already approved as part of Biktarvy, while lenacapavir is a first-in-class capsid inhibitor with a novel mechanism that disrupts the HIV capsid at multiple stages of the viral life cycle and carries no cross-resistance with existing antiretroviral drug classes.
The NDA draws on data from the ARTISTRY-1 and ARTISTRY-2 clinical trials. In ARTISTRY-1, adults on complex multi-drug HIV regimens were randomised 2:1 to switch to once-daily BIC/LEN or continue on their existing treatment; BIC/LEN maintained virological suppression non-inferiorly. A simplified single-tablet regimen holds meaningful quality-of-life value for people living with HIV, particularly those currently on multi-drug combinations. The FDA granted Priority Review for the application; a PDUFA date represents the target by which the agency aims to complete its review, not a guaranteed approval.
This article is a journalistic summary of health and medicine developments and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health routines.